es, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.
This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.
Competitor projects are listed in a tabular format providing Information on:
• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Product Category,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents
1) Erythropoiesis Stimulating Agents (ESA)
• First generation epoetins in regulated markets
• Second generation epoetins in regulated markets
• Epoetin biosimilars in regulated markets
• Darbepoetin biosimilars in regulated markets
• Next generation biologic Eythropoiesis Stimulating Agents (ESA) in Page: 1 2 3 4 5 6 7 8 Related biology technology :1
. Cell Therapeutics to Present at Upcoming Investor Conferences2
. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference3
. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics4
. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 20135
. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug6
. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors7
. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer8
. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies9
. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 201310
. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 201311
. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures